Business
Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria
Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n ORLANDO, Fla., Feb. 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) (\"Immune\" “IMUN” or the \"Company\"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal” and IRT-101 “MENK”) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs,  today announced the company has shipped its initial order of Lodonal to AHAR Pharma in Nigeria.\n  In addition, IMUN has received both trademark and patent approval from the Federal Republic of Nigeria giving the Company ironclad protection of its ideas, inventions, designs, and trade secrets while also ensuring IMUN legal rights are not infringed upon. Immune Therapeutics shipped 100,000 capsules of Lodonal fulfilling the initial purchase order for $195,000 with AHAR Pharma, Immune’s agent and distributor in Nigeria.  Since the company’s shipment has recently cleared customs, it is now available via AHAR in Nigeria. The company has received a Certificate of Patent Approval for Lodonal NG/P/2017/602 and Certificate of Registration of Design (Trademark, Name, Box Design) NG/D.2017/603. CEO Noreen Griffin states, “The initial Lodonal order to Nigeria is just the beginning for us with many more to come based on our strong relationship with AHAR and our ability to expand our reach in the African country through a number of potential sub-distributors for sales and marketing.” “While we are focused on an aggressive marketing strategy of Lodonal in Nigeria it is vital for us to register and protect our intellectual property rights there as well especially due to the fact that we are a non-Nigerian business desiring to take a slice of the almost 200 Million strong import-dependent domestic market which Nigeria represents.  We also believe it forestalls potential pirating and counterfeiting of our products as well.” “Immune and AHAR are currently completing the necessary regulatory paperwork for presentation to the National Agency for Food and Drug Administration and Control (NAFDAC) for the approval of Lodonal for a number of additional indications.” Griffin said she believes the company will be ready to submit to NAFDAC in Q1 of 2018.  The company pl...